Compare Tango Therapeutics Inc. (TNGX) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Ventas Inc. Common Stock — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Ventas Inc. Common Stock trades at $85.53 (market cap $43.01B). The key difference: Ventas Inc. Common Stock is far larger — about 11.5× Tango Therapeutics Inc.'s market cap, and Ventas Inc. Common Stock pays a 2.48% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Ventas Inc. Common Stock for 6 Days on average.
| TNGX | VTR | |
|---|---|---|
Market Cap | $3.75B | $43.01B |
Volume | 9,619,106 | 4,035,460 |
Sector | Health | Real Estate |
52-Week High | $32.90 | $100.53 |
52-Week Low | $7.50 | $68.89 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.77B | $55.73B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Ventas (VTR) trades at $83.85, up 0.37% today, amid a bearish technical signal with resistance near $84. The REIT reported Q2 2026 EPS of $0.14, slightly missing expectations, but maintains strong revenue growth with 2026 guidance at $6.4B. Analyst sentiment is positive with a $99.14 consensus target, supported by demographic tailwinds in senior housing.
The outlook for VTR is cautiously optimistic, driven by aging population trends boosting demand for senior housing. Risks include high valuation multiples and negative cash flow from aggressive investing. Wall Street's buy ratings (56%) suggest confidence in long-term growth, but investors should monitor earnings consistency and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
